Conversion to high dose gabapentin monotherapy in patients with medically refractory partial epilepsy

Epilepsia

Volumn 39, Issue 2, 1998, Pages 188-193

  Beydoun, A ^a,c   Fakhoury, T ^b   Nasreddine, W ^a   Abou Khalil, B ^b  

^a UNIVERSITY OF MICHIGAN   (United States)

^b VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

Antiepileptic drug; Gabapentin; Monotherapy

Indexed keywords

GABAPENTIN;

ADULT; ARTICLE; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DOSE RESPONSE; DOUBLE BLIND PROCEDURE; DRUG BLOOD LEVEL; DRUG EFFICACY; DRUG SAFETY; FATIGUE; FEMALE; FOCAL EPILEPSY; HEADACHE; HUMAN; MALE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SOMNOLENCE; WEIGHT GAIN;

ACETIC ACIDS; ADULT; AMINES; ANTICONVULSANTS; CYCLOHEXANECARBOXYLIC ACIDS; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; EPILEPSIES, PARTIAL; FEMALE; FOLLOW-UP STUDIES; GAMMA-AMINOBUTYRIC ACID; HUMANS; MALE; MEDICAL RECORDS; MIDDLE AGED; THERAPEUTIC EQUIVALENCY; TREATMENT OUTCOME;

EID: 0031908243     PISSN: 00139580     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1528-1157.1998.tb01357.x     Document Type: Article

References (22)

1. U.K. Gabapentin Study Group. Gabapentin in partial epilepsy. Lancet 1990;335:1114-7.
2. The U.S. Gabapentin Study Group No. 5. Gabapentin as add-on therapy in refractory partial epilepsy: a double-blind, placebo-controlled, parallel-group study. Neurology 1993;43:2292-8.
3. Anhut H, Ashman P, Feuerstein TJ, Sauermann W, Saunders M, Schmidt B. Gabapentin (Neurontin) as add-on therapy in patients with partial seizures: a double-blind, placebo-controlled study. The International Gabapentin Study Group. Epilepsia 1994;35:795-801.
4. Bergey GK, Morris HH, Rosenfeld W, et al. Gabapentin Monotherapy: I. An 8-day, double-blind, dose-controlled, multicenter study in hospitalized patients with refractory complex partial or secondarily generalized seizures. Neurology 1997;49:739-45.
5. Beydoun A, Fischer J, Labar DR, et al. Gabapentin Monotherapy: II. A 26-week, double-blind, dose-controlled, multicenter study of conversion from polytherapy in outpatients with refractory complex partial or secondarily generalized seizures. Neurology 1997; 49:746-52.
6. Chadwick D, Anhut H, Murray G, Greiner M, Alexander J, Int. Gabapentin Monotherapy Study Group (945-077). Gabapentin monotherapy in patients with newly-diagnosed epilepsy: results of a double-blind fixed-dose study comparing three dosages of gabapentin and open-label carbamazepine. Epilepsia, 1997;38(suppl 3): 34.
7. Ojemann LM, Wilensky AJ, Temkin NR, Chmelir T, Ricker BA, Wallace J. Long-term treatment with gabapentin for partial epilepsy. Epilepsy Res 1992;13:159-65.
8. Krauss GL, Simmons-O'Brien E, Campbell M. Successful treatment of seizures and porphyria with gabapentin. Neurology 1995; 45:594-5.
9. Tatum WO, Zachariah SB. Gabapentin treatment of seizures in acute intermittent porphyria. Neurology 1995;45:1216-7.
10. Leidermann DB. Gabapentin as add-on therapy for refractory partial epilepsy: results of five placebo-controlled studies. Epilepsia 1994;33(suppl 5):S74-6.
11. Crawford P, Ghadiali E, Lane R, Blumhardt L, Chadwick D. Gabapentin as an antiepileptic drug in man. J Neurol Neurosurg Psychiatry 1987;50:682-6.
12. Bauer G, Bechinger D, Castell M, et al. Gabapentin in the treatment of drug-resistant epileptic patients. Adv Epileptol 1989;17: 219-21.
13. Abou-Khalil B, Shellenberger MK, Anhut H. Two open-label multicenter studies of the safety and efficacy of gabapentin in patients with refractory epilepsy. Epilepsia 1992;33(suppl. 3):77.
14. Sivenius J, Ylinen A, Kalviainen R, Riekkinen P. Long-term study with gabapentin in patients with drug-resistant epileptic seizures. Arch Neurol 1994;51:1047-50.
15. Handforth A, Treiman DM. Efficacy and tolerance of long-term, high-dose gabapentin: additional observations. Epilepsia 1994;35:1032-7.
16. The U.S. Gabapentin Study Group. The long-term safety and efficacy of gabapentin (Neurontin) as add-on therapy in drug-resistant partial epilepsy. Epilepsy Res 1994;18:67-73.
17. Richens A. Clinical pharmacokinetics of gabapentin. In: Chadwick D, ed. New trends in epilepsy management: the role of gabapentin. London. Royal Society of Medicine Services; 1993:41-6.
18. Stewart BH, Kugler AR, Thompson PR, Bockbrader HN. A saturable transport mechanism in the intestinal absorption of gabapentin is the underlying cause of lack of proportionality between increasing dose and drug levels in plasma. Pharm Res 1993;10:276-81.
19. Sivenius J, Kalviainen R, Ylinen A, Riekkinen P. Double-blind study of gabapentin in the treatment of partial seizures. Epilepsia 1991;32:539-42.
20. Taylor CP. Gabapentin: mechanisms of action. In: Levy RH, Mattson RH, Meldrum BS, EDS., Antiepileptic Drugs. 4th ed. New York, New York. Raven Press, 1995:829-41.
21. Asconape J, Collins T. Weight gain associated with the use of gabapentin. Epilepsia 1995;36(suppl 4):72.
22. King JA, Bayles RL. Weight gain during add-on therapy using gabapentin (GBP). Epilepsia 1995;36(suppl 4):72.